medwireNews: Resource utilisation data from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial show that the most efficacious drug for diabetic macular oedema, aflibercept, is not cost-effective relative to repackaged bevacizumab.
And neither is ranibizumab cost-effective, being less expensive than aflibercept but also less effective, researcher Adam Glassman (Jaeb Center for Health Research, Tampa, Florida, USA) and team report in JAMA Ophthalmology.
Over 1 year, the incremental cost-effectiveness ratio (ICER) versus bevacizumab was US$ 1,110,000 (€ 986,623) per quality-adjusted life–year (QALY) for aflibercept and $ 1,730,000 (€ 1,537,709) for ranibizumab. And the corresponding projected 10-year ICERs were $ 349,000 (€ 310,208) and $ 603,000 (€ 535,976) per QALY.
All of these are “substantially higher” than the commonly quoted ICER thresholds, say the researchers, which “highlight the challenges that physicians, patients, and policymakers face when safety and efficacy results are at odds with cost-effectiveness results.”
medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2016